Grant of Share Options

AI SummaryClose X

Shield Therapeutics plc announced on May 5, 2026, that its Chief Executive Officer, Anders Lundstrom, was granted 5,162,294 share options under the company's Retention and Performance Share Plan. These options, representing approximately 0.48% of the total AIM securities in issue, have an exercise price of £0.079 and will vest three years from the grant date, contingent on Mr. Lundstrom remaining in his role. This grant follows Mr. Lundstrom's existing holding of 585,000 ordinary shares.

Disclaimer*

UK 100

Latest directors dealings